These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1801560)

  • 1. Intravenous gamma-globulin for Kawasaki disease.
    Furusho K; Kamiya T; Nakano H; Kiyosawa N; Shinomiya K; Hayashidera T; Tamura T; Hirose O; Manabe Y; Yokoyama T
    Acta Paediatr Jpn; 1991 Dec; 33(6):799-804. PubMed ID: 1801560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
    Furukawa S; Matsubara T; Umezawa Y; Motohashi T; Ino T; Yabuta K
    Eur J Pediatr; 1994 Sep; 153(9):663-7. PubMed ID: 7957426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous gamma-globulin treatment in Kawasaki disease.
    Harada K
    Acta Paediatr Jpn; 1991 Dec; 33(6):805-10. PubMed ID: 1801561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M; Imagawa T; Yasui K; Kanaya A; Yokota S
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N; Sugimura T; Akagi T; Yamakawa R; Hashino K; Eto G; Iemura M; Ishii M; Kato H
    Pediatr Int; 1999 Feb; 41(1):1-7. PubMed ID: 10200128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
    Miura M; Ohki H; Tsuchihashi T; Yamagishi H; Katada Y; Yamada K; Yamashita Y; Sugaya A; Komiyama O; Shiro H
    Arch Dis Child; 2004 Aug; 89(8):776-80. PubMed ID: 15269082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intravenous gamma-globulin on neutrophil function in Kawasaki disease.
    Okada M; Satoh T; Hayashi T
    Acta Paediatr Jpn; 1991 Dec; 33(6):785-90. PubMed ID: 1801558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease.
    Qin L; Saumu MT; Wang H; Shi H; Hu X; Cheng P
    J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):348-50, 370. PubMed ID: 16201293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.
    Hsu CH; Chen MR; Hwang FY; Kao HA; Hung HY; Hsu CH
    Pediatr Infect Dis J; 1993 Jun; 12(6):509-12. PubMed ID: 8345983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kawasaki disease in infants less than one year of age.
    Rosenfeld EA; Corydon KE; Shulman ST
    J Pediatr; 1995 Apr; 126(4):524-9. PubMed ID: 7699529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.
    Terai M; Shulman ST
    J Pediatr; 1997 Dec; 131(6):888-93. PubMed ID: 9427895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiac involvement in Kawasaki disease. Our experience].
    Sciacca P; Falsaperla R; Barone P; Tornambene G; Mattia C; Marletta M; Betta P; Distefano G
    Minerva Pediatr; 2001 Apr; 53(2):87-93. PubMed ID: 11404729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do we have a less severe form of Kawasaki disease or is it the gammaglobulin effect?
    Abushaban L; Salama A; Uthaman B; Kumar A; Selvan J
    Int J Cardiol; 1999 Apr; 69(1):71-6. PubMed ID: 10362375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New hope for children with Kawasaki disease.
    Lux KM
    J Pediatr Nurs; 1991 Jun; 6(3):159-65. PubMed ID: 1710660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical manifestations and effects of IVGG in patients with Kawasaki disease].
    Hwang KP; Wu JR; Huang LY; Liou CC; Huang TY
    Kaohsiung J Med Sci; 1996 Mar; 12(3):159-66. PubMed ID: 8709183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between maternal age and outcomes in Kawasaki disease patients.
    Huang WD; Lin YT; Tsai ZY; Chang LS; Liu SF; Lin YJ; Kuo HC
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):46. PubMed ID: 31324255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose intravenous gammaglobulin for Kawasaki disease.
    Furusho K; Kamiya T; Nakano H; Kiyosawa N; Shinomiya K; Hayashidera T; Tamura T; Hirose O; Manabe Y; Yokoyama T
    Lancet; 1984 Nov; 2(8411):1055-8. PubMed ID: 6209513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Labeled WBC cardiac imaging and two-dimensional echocardiography to evaluate high-dose gamma globulin treatment in Kawasaki disease.
    Kao CH; Hsieh KS; Chen YC; Wang YL; Wang SJ; Yeh SH
    Clin Nucl Med; 1995 Sep; 20(9):813-6. PubMed ID: 8521660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients diagnosed with Kawasaki disease before the fifth day of illness have a higher risk of coronary artery aneurysm.
    Nomura Y; Masuda K; Yoshinaga M; Sameshima K; Miyata K
    Pediatr Int; 2002 Aug; 44(4):353-7. PubMed ID: 12139556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of intravenous gamma-globulin for Kawasaki disease: effects on cardiac sequelae.
    Yanagawa H; Nakamura Y; Sakata K; Yashiro M
    Pediatr Cardiol; 1997; 18(1):19-23. PubMed ID: 8960487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.